Intelligence Feed event · Policy · 2026-09-12

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Question

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Direct answer

    Scholar Rock obtained FDA approval for Isembyld (apitegromab-mstn), establishing the first muscle-targeted therapy for patients with spinal muscular atrophy. The decision was based on Phase 3 SAPPHIRE trial data demonstrating clinically meaningful gains in motor function when administered alongside standard SMN therapies.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/fda-approves-scholar-rock-s-isembyld-for-spinal-muscular-atrophy-d550e3

    POLICY
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    Scholar Rock obtained FDA approval for Isembyld (apitegromab-mstn), establishing the first muscle-targeted therapy for patients with spinal muscular atrophy. The decision was based on Phase 3 SAPPHIRE trial data demonstrating clinically meaningful gains in motor function when administered alongside standard SMN therapies.
    SRRK
    Impact
    75
    SEP 12
    SIG
    95%
    SRRK
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    Scholar Rock obtained FDA approval for Isembyld (apitegromab-mstn), establishing the first muscle-targeted therapy for patients with spinal muscular atrophy. The decision was based on Phase 3 SAPPHIRE trial data demonstrating clinically meaningful gains in motor function when administered alongside standard SMN therapies.
    → Regulatory approval unlocks commercial monetization and market entry in spinal muscular atrophy treatment for Scholar Rock.
    Impact
    Scholar Rock obtained FDA approval for Isembyld (apitegromab-mstn), establishing the first muscle-targeted therapy for patients with spinal muscular atrophy. The decision was based on Phase 3 SAPPHIRE trial data demonstrating clinically meaningful gains in motor function when administered alongside standard SMN therapies.
    Affected
    SRRK
    Transmission
    Regulatory approval unlocks commercial monetization and market entry in spinal muscular atrophy treatment for Scholar Rock.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SRRKcommercial product revenue generation from FDA market approvalUp1-5dThe FDA has approved Isembyld (apitegromab-mstn) based on positive Phase 3 SAPPHIRE study results.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month